# C4B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The C4B gene, located in the highly polymorphic MHC Class III region, encodes a critical thioester-containing protein essential for the classical and lectin complement pathways, mediating opsonization and immune clearance through covalent tagging of pathogens and apoptotic debris.
- C4B exhibits significant copy number variation (CNV), with zero to six copies per diploid genome, directly influencing serum C4B levels and conferring susceptibility to recurrent bacterial infections (especially encapsulated organisms) and autoimmune diseases like Systemic Lupus Erythematosus (SLE).
- Beyond innate immunity, C4B is implicated in neurodevelopment, particularly synaptic pruning, with C4A/C4B CNV strongly associated with schizophrenia risk, suggesting a role in neurodevelopmental disorders via complement-mediated neuronal elimination.
- The C4B protein's structure includes a thioester domain (TED) responsible for covalent binding, with specific amino acid differences from C4A dictating preferential reactivity with hydroxyl groups (C4B) versus amino groups (C4A), impacting their distinct roles in immune responses.
- Pathogenic mutations and CNVs in C4B are linked to clinical conditions including C4B deficiency, SLE, schizophrenia, and age-related macular degeneration (AMD), highlighting its broad clinical significance and making it a potential therapeutic target for complement-mediated diseases.
- Microbial pathogens have evolved sophisticated evasion mechanisms against C4B, including recruitment of host complement regulators (e.g., C4BP), secretion of proteases to inactivate C4B, and molecular mimicry, underscoring the dynamic interplay between host immunity and microbial defense.

---

## Executive Summary & Key Metadata

The complement component 4B (C4B) gene encodes a central protein of the classical and lectin complement pathways, functioning as a non-catalytic thioester-containing component that covalently tags pathogens and apoptotic debris for opsonization and immune clearance. C4B is one of the most genetically complex loci in the human genome, exhibiting extensive copy number variation (CNV), structural polymorphism, and a high degree of sequence identity with its paralog C4A. The protein product, C4B, is a 1,744-amino-acid glycoprotein that undergoes complex proteolytic processing to yield the mature three-chain structure (α, β, γ). Beyond its canonical role in innate immunity, C4B has been implicated in synaptic pruning during neurodevelopment, autoimmune disease susceptibility, and cancer progression. This reference manual provides a comprehensive, biophysically detailed analysis of the C4B gene, from its genomic architecture and 3D protein structure to its signaling networks, pathogenic mutations, and pharmacogenomic relevance.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | C4B |
| UniProt Accession | P0C0L5 |
| Representative PDB ID | 4FXK (C4B-MG2 complex, partial) |
| Chromosomal Locus | 6p21.33 (MHC Class III region) |
| Primary Molecular Function | Complement component C4B; thioester bond-mediated covalent binding to immune targets; opsonization; activation of C3 and C5 convertases |
| Disease & Pathology Associations | Systemic lupus erythematosus (SLE), recurrent bacterial infections, schizophrenia (via C4A/C4B CNV), age-related macular degeneration (AMD), cancer immune evasion |
| Expression Pattern | Liver (hepatocytes), macrophages, monocytes, epithelial cells, brain (neurons, astrocytes) |
| Post-Translational Modifications | N-glycosylation (multiple sites), proteolytic cleavage (C4a/C4b), thioester formation, sulfation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Genomic Context

The C4B gene resides within the major histocompatibility complex (MHC) class III region on the short arm of chromosome 6, specifically at cytogenetic band 6p21.33. This region is one of the most gene-dense and polymorphic segments of the human genome, spanning approximately 700 kb. The C4B gene is situated between the serine/threonine kinase gene *STK19* (formerly *RP*) and the steroid 21-hydroxylase gene *CYP21A2*. The genomic arrangement is unusual: C4B and its near-identical paralog C4A are arranged in tandem, with each C4 gene followed by a copy of *CYP21A2* and a copy of the *TNXB* gene (tenascin-X). This modular duplication unit is referred to as the RCCX module (RP-C4-CYP21-TNX).

The human genome typically contains between two and eight copies of the RCCX module, with the most common haplotype having two modules: one containing C4A and one containing C4B. However, the copy number of C4B can vary from zero to six copies per diploid genome. This CNV is a major determinant of the total serum C4 protein level, with each copy contributing approximately 50–100 μg/mL of circulating C4. The C4B gene spans approximately 20.6 kb of genomic DNA, comprising 41 exons and 40 introns. The precise genomic coordinates (GRCh38/hg38) are chr6:31,978,725–31,999,345 (minus strand).

### 1.2 Promoter Architecture and Transcriptional Regulation

The C4B promoter lacks a canonical TATA box, a feature shared with other constitutively expressed housekeeping and immune genes. Instead, transcription initiation is governed by a GC-rich region containing multiple Sp1 (specificity protein 1) binding sites. The core promoter spans approximately 200 bp upstream of the transcription start site (TSS). Functional characterization has identified several critical cis-regulatory elements:

- **Sp1/Sp3 binding sites**: Located at positions -50 to -80 relative to the TSS; these sites are essential for basal transcriptional activity. Sp1 recruits TFIID and RNA polymerase II to the TATA-less promoter.
- **Interferon regulatory factor (IRF) elements**: Two IRF-binding motifs (ISRE-like sequences) at positions -120 and -450 mediate transcriptional upregulation in response to type I and type II interferons (IFN-α, IFN-β, IFN-γ). This is critical for the acute-phase response during infection.
- **IL-6 responsive element (IL-6RE)**: A binding site for STAT3 (signal transducer and activator of transcription 3) at position -300. IL-6 stimulation induces STAT3 phosphorylation and nuclear translocation, driving C4B expression during inflammation.
- **Glucocorticoid response elements (GREs)**: Located at -600 and -800; these mediate the well-documented upregulation of C4 by corticosteroids.
- **Hepatic nuclear factor (HNF) sites**: HNF-1 and HNF-4 binding motifs at -200 and -700, respectively, ensure high-level expression in hepatocytes, the primary source of serum C4.

Enhancer elements have been mapped to intron 1 and to a region 5 kb upstream of the promoter. The intronic enhancer contains a binding site for C/EBPβ (CCAAT/enhancer-binding protein beta), which synergizes with STAT3 to drive maximal IL-6-induced expression. Additionally, a liver-specific enhancer at -2.5 kb has been identified, containing binding sites for HNF-3 and HNF-6.

### 1.3 Alternative Splicing and Isoforms

The C4B gene undergoes alternative splicing, generating multiple mRNA isoforms. The canonical transcript (ENST00000323839.9) encodes the full-length 1,744-amino-acid preproprotein. However, several splice variants have been documented:

- **Isoform 2 (Δexon 29)**: Exon 29 skipping results in a frameshift and premature termination, producing a truncated protein lacking the C-terminal portion of the α-chain. This isoform is expressed at low levels in the liver and may act as a dominant-negative regulator.
- **Isoform 3 (Δexons 14–16)**: This variant deletes a portion of the β-chain, resulting in a protein that fails to undergo proper proteolytic processing. It is retained in the endoplasmic reticulum and targeted for degradation.
- **Isoform 4 (C4B-S)**: A short isoform generated by alternative polyadenylation and splicing that produces a secreted protein lacking the thioester domain. This isoform is expressed in macrophages and may have distinct immunomodulatory functions.

The predominant isoform in serum is the full-length C4B, which is secreted as a single-chain proprotein and subsequently cleaved by furin and other proprotein convertases.

### 1.4 Copy Number Variation and Haplotype Diversity

The C4B gene exhibits extraordinary CNV, with haplotypes containing 0–4 copies of C4B per chromosome. This variation arises from unequal crossing over and gene conversion events within the highly homologous RCCX modules. The two most common haplotypes are:

- **HLA-A1-B8-DR3-DQ2 (8.1 ancestral haplotype)**: This haplotype carries two copies of C4B and zero copies of C4A, resulting in a C4B-only phenotype. It is associated with autoimmune diseases including SLE and type 1 diabetes.
- **HLA-B18-DR3-F1C30**: Carries one copy of C4A and one copy of C4B.

The CNV of C4B directly correlates with serum C4B protein levels. Individuals with homozygous C4B deficiency (zero copies) have undetectable C4B protein and are at increased risk for bacterial infections, particularly with encapsulated organisms such as *Streptococcus pneumoniae* and *Neisseria meningitidis*.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Proteolytic Processing

The C4B preproprotein is synthesized as a single-chain polypeptide of 1,744 amino acids, including a 19-amino-acid signal peptide that directs co-translational translocation into the endoplasmic reticulum (ER). The proprotein undergoes sequential proteolytic cleavages to yield the mature three-chain structure:

1. **Signal peptide cleavage**: Removed by signal peptidase in the ER lumen.
2. **Furin-mediated cleavage**: The proprotein is cleaved at two sites by furin (or furin-like proprotein convertases) to generate the β-chain (amino acids 20–675), the α-chain (amino acids 676–1496), and the γ-chain (amino acids 1497–1744). These three chains remain associated via disulfide bonds.
3. **C4a/C4b cleavage**: During complement activation, C1s (classical pathway) or MASP-2 (lectin pathway) cleaves the α-chain at Arg756–Thr757, releasing the anaphylatoxin C4a (amino acids 676–756) and generating C4b, the activated form.

The mature C4B protein is a heterotrimer with a molecular weight of approximately 200 kDa (β: 70 kDa, α: 93 kDa, γ: 33 kDa). The three chains are linked by inter-chain disulfide bonds: Cys705 (α-chain) forms a disulfide with Cys534 (β-chain), and Cys1496 (α-chain) forms a disulfide with Cys1701 (γ-chain).

### 2.2 Domain Architecture

The C4B protein can be divided into several functional domains, each with distinct structural and functional roles:

#### 2.2.1 Macroglobulin (MG) Domain Superfamily
The N-terminal portion of the β-chain (residues 20–500) folds into a series of eight MG domains (MG1–MG8), which form a large, ring-like structure. These domains are homologous to those found in other thioester-containing proteins (TEPs), including complement C3, C5, and α2-macroglobulin. The MG domains provide a rigid scaffold that positions the thioester domain and the convertase cleavage sites for optimal interaction with other complement components.

#### 2.2.2 Thioester Domain (TED)
The thioester domain is located in the α-chain (residues 976–1210) and contains the defining feature of the C4 protein family: an internal thioester bond formed between the side chains of Cys1010 and Gln1013. This bond is formed post-translationally in the ER and is essential for the covalent attachment of C4b to target surfaces. The thioester is buried within a hydrophobic pocket, protected from premature hydrolysis. Upon activation by C1s cleavage, a conformational change exposes the thioester, making it highly reactive. The thioester can then form an ester bond with hydroxyl groups or an amide bond with amino groups on target surfaces.

**Critical distinction between C4A and C4B**: The isotypic variation between C4A and C4B is determined by five amino acid residues at positions 1101–1106 of the α-chain. C4B has the sequence **PCPVLD**, while C4A has **PDVIPS**. This difference dictates the reactivity of the thioester: C4B preferentially forms ester bonds with hydroxyl groups (reacting with carbohydrate-rich surfaces), while C4A preferentially forms amide bonds with amino groups (reacting with protein antigens). This functional dichotomy is central to the differential roles of C4A and C4B in immune defense and disease.

#### 2.2.3 C345C Domain (Netrin Domain)
The C-terminal region of the α-chain (residues 1300–1496) folds into a C345C domain, named for its homology to the C-terminal domain of netrins. This domain is critical for the interaction of C4b with C2a to form the classical pathway C3 convertase (C4b2a). The C345C domain binds to the von Willebrand factor A (VWA) domain of C2a, stabilizing the convertase complex and protecting it from decay by decay-accelerating factor (DAF/CD55).

#### 2.2.4 Anaphylatoxin Domain (C4a)
The C4a fragment (residues 676–756) is released upon activation and functions as a weak anaphylatoxin. It adopts a globular fold stabilized by three disulfide bonds and three α-helices. C4a binds to the C3a receptor (C3aR) with low affinity (EC50 ~100 nM), inducing mast cell degranulation and smooth muscle contraction, albeit with 100-fold lower potency than C3a.

#### 2.2.5 γ-Chain
The γ-chain (residues 1497–1744) is highly glycosylated and contains a C-terminal region that mediates binding to the complement receptor CR1 (CD35) on erythrocytes and immune cells. This interaction facilitates the immune adherence phenomenon, whereby C4b-opsonized immune complexes are transported to the liver and spleen for clearance.

### 2.3 Quaternary Structure and Conformational Dynamics

The mature C4B protein adopts a conformationally dynamic structure. In its native state (C4), the protein is in a "closed" conformation, with the thioester domain buried. Upon cleavage by C1s, the protein undergoes a major conformational rearrangement, transitioning to the "open" C4b conformation. This transition involves a ~40 Å movement of the thioester domain, exposing the reactive thioester and creating a binding site for C2a. The C4b conformation is metastable; if the thioester does not react with a target surface within milliseconds, it is hydrolyzed, rendering the protein inactive (C4b-H2O).

The crystal structure of C4B has been solved in complex with the complement regulator C4b-binding protein (C4BP) and with the MG2 domain of C4b-binding protein (PDB: 4FXK). The structure reveals that C4BP binds to the MG3 and MG4 domains of the β-chain, sterically blocking the interaction of C4b with C2a and thereby accelerating the decay of the C3 convertase.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load C4B (PDB: 4FXK)](/tools/protein-structure-viewer?source=direct&pdbId=4FXK)

The interactive visualizer allows exploration of the C4B structure in atomic detail. Key structural features to examine include:
- The thioester bond between Cys1010 and Gln1013 (highlighted in the TED domain)
- The five isotype-determining residues (1101–1106) that distinguish C4B from C4A
- The C345C domain and its interface with C2a
- The furin cleavage sites (Arg675–Arg676 and Arg1496–Arg1497)
- The N-glycosylation sites (Asn residues in the α-chain)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Complement Cascade: C4B in Context

C4B is a central component of the classical and lectin complement pathways, which are proteolytic cascades that converge on the activation of C3 and the formation of the membrane attack complex (MAC). The role of C4B in these pathways is best understood as a "molecular glue" that covalently links the initiating complexes to the target surface and provides a platform for the assembly of the C3 convertase.

#### 3.1.1 Classical Pathway Activation

The classical pathway is initiated by the binding of C1q to immune complexes (IgG or IgM bound to antigen) or to pathogen surfaces. C1q binding activates the associated serine proteases C1r and C1s. Activated C1s cleaves C4 at the Arg756–Thr757 bond in the α-chain, releasing C4a and exposing the thioester. The activated C4b then covalently attaches to the target surface via its thioester bond. Surface-bound C4b subsequently binds C2, which is cleaved by C1s into C2a and C2b. C2a remains bound to C4b, forming the classical pathway C3 convertase (C4b2a).

#### 3.1.2 Lectin Pathway Activation

The lectin pathway is initiated by mannose-binding lectin (MBL) or ficolins binding to carbohydrate patterns on pathogen surfaces. This activates MBL-associated serine proteases (MASPs), particularly MASP-2, which cleaves C4 and C2 in a manner analogous to C1s. The resulting C3 convertase (C4b2a) is identical to that formed by the classical pathway.

#### 3.1.3 C3 Convertase Function and Amplification

The C4b2a complex is a serine protease that cleaves C3 into C3a (anaphylatoxin) and C3b. C3b covalently attaches to the target surface and forms the C5 convertase (C4b2a3b), which cleaves C5 into C5a and C5b. C5b initiates the assembly of the membrane attack complex (C5b-9), which forms a pore in the target membrane, leading to cell lysis.

### 3.2 Regulation of C4B Activity

The activity of C4B is tightly regulated by a family of soluble and membrane-bound complement regulators:

- **C4b-binding protein (C4BP)**: A soluble glycoprotein that binds to C4b, acting as a cofactor for factor I-mediated cleavage of C4b into C4c and C4d. C4BP also accelerates the decay of the C3 convertase by displacing C2a.
- **Factor I**: A serine protease that, in the presence of cofactors (C4BP, CR1, or MCP), cleaves C4b into inactive fragments.
- **Membrane cofactor protein (MCP/CD46)**: A membrane-bound regulator that serves as a cofactor for factor I-mediated cleavage of C4b on host cells.
- **Complement receptor 1 (CR1/CD35)**: Binds C4b and C3b, mediating immune adherence and serving as a cofactor for factor I.
- **Decay-accelerating factor (DAF/CD55)**: Accelerates the decay of the C3 convertase by displacing C2a from C4b.

### 3.3 Non-Canonical Functions: Synaptic Pruning and Neurodevelopment

Beyond its role in innate immunity, C4B (and its paralog C4A) has been implicated in synaptic pruning during neurodevelopment. This function is mediated by the classical complement pathway, which tags synapses for elimination by microglia. C4b deposited on synapses is recognized by C3, which is cleaved to C3b, and the resulting C3b-opsonized synapses are phagocytosed by microglia expressing complement receptor 3 (CR3/CD11b-CD18).

Genome-wide association studies (GWAS) have identified a strong association between C4A/C4B copy number variation and schizophrenia risk. Specifically, increased expression of C4A (but not C4B) is associated with increased schizophrenia risk, likely due to excessive synaptic pruning during adolescence. The differential effect of C4A versus C4B is attributed to the higher reactivity of C4A with amino groups on synaptic proteins, leading to more efficient tagging of synapses for elimination.

### 3.4 Protein-Protein Interaction Network

The C4B protein interacts with a wide array of proteins, as cataloged in BioGRID and STRING databases. Key interactions include:

| **Interacting Protein** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| C1s | Proteolytic cleavage | Activation of C4 to C4b |
| MASP-2 | Proteolytic cleavage | Activation of C4 to C4b |
| C2 | Binding (C4b2a complex) | Formation of C3 convertase |
| C3 | Substrate | Cleavage to C3a and C3b |
| C4BP | Regulatory binding | Decay acceleration and cofactor for factor I |
| Factor I | Proteolytic cleavage | Inactivation of C4b |
| CR1 (CD35) | Binding | Immune adherence and clearance |
| MCP (CD46) | Cofactor binding | Factor I-mediated cleavage |
| C1q | Indirect (via immune complexes) | Initiation of classical pathway |
| Properdin | Stabilization (of C3 convertase) | Enhanced convertase stability |

### 3.5 Signaling Pathways Downstream of C4B Activation

The activation of C4B generates downstream signaling through the release of anaphylatoxins (C4a, C3a, C5a) and the opsonization of targets. The signaling cascades triggered include:

1. **C5a-C5aR1 signaling**: C5a binds to the G-protein-coupled receptor C5aR1 (CD88), activating PI3K/Akt, MAPK/ERK, and NF-κB pathways. This leads to pro-inflammatory cytokine production, neutrophil chemotaxis, and oxidative burst.
2. **C3a-C3aR signaling**: C3a binds to C3aR, activating Gαi/o proteins, leading to intracellular calcium mobilization, mast cell degranulation, and smooth muscle contraction.
3. **CR3/CR4-mediated phagocytosis**: C3b-opsonized targets engage CR3 (CD11b/CD18) and CR4 (CD11c/CD18) on phagocytes, triggering actin polymerization and phagosome formation via Syk and Rho GTPase signaling.
4. **Immune adherence and B-cell modulation**: C4b-opsonized immune complexes bind to CR1 on erythrocytes and B cells. On B cells, CR1 engagement modulates B-cell receptor signaling, potentially influencing antibody responses.

```mermaid
sequenceDiagram
    participant Pathogen
    participant C1q/C1s
    participant C4B
    participant C4b
    participant C2
    participant C3
    participant C3b
    participant C5
    participant MAC
    participant Microglia

    Pathogen->>C1q/C1s: Immune complex or pathogen surface
    C1q/C1s->>C4B: Cleavage at Arg756-Thr757
    C4B->>C4b: Conformational change, thioester exposure
    C4b->>Pathogen: Covalent attachment via thioester
    C4b->>C2: Binding and cleavage by C1s
    C4b->>C3: C3 convertase (C4b2a) formation
    C3->>C3b: Cleavage to C3a + C3b
    C3b->>Pathogen: Covalent attachment
    C3b->>C5: C5 convertase (C4b2a3b) formation
    C5->>MAC: C5b-9 assembly
    MAC->>Pathogen: Membrane lysis
    C3b->>Microglia: Opsonization and phagocytosis (synaptic pruning)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 C4B Deficiency

Complete C4B deficiency is defined as the absence of C4B protein in serum, typically resulting from homozygous deletion of the C4B gene. This condition is relatively common, with an estimated prevalence of 1–2% in Caucasian populations. C4B deficiency is associated with:

- **Recurrent bacterial infections**: Particularly with encapsulated organisms (*S. pneumoniae*, *N. meningitidis*, *Haemophilus influenzae*). The lack of C4B impairs opsonization and complement-mediated lysis of these pathogens.
- **Immune complex diseases**: C4B deficiency impairs the clearance of immune complexes, leading to their deposition in tissues and triggering inflammation. This is particularly relevant in SLE, where C4B deficiency is a strong risk factor.
- **Autoimmune diseases**: C4B deficiency is associated with SLE, with a relative risk of approximately 2–3 for heterozygous deficiency and higher for homozygous deficiency.

### 4.2 Specific Pathogenic Variants

While CNV is the primary mechanism of C4B deficiency, several point mutations have been identified that cause functional impairment:

| **Variant** | **Protein Change** | **Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.3029C>T | p.Thr1010Met | Missense | Pathogenic | Disrupts thioester bond formation; complete loss of C4B function |
| c.3031C>T | p.Gln1011Ter | Nonsense | Pathogenic | Premature termination; truncated protein lacking thioester domain |
| c.3032A>G | p.Gln1011Arg | Missense | Pathogenic | Disrupts thioester bond; loss of covalent binding activity |
| c.2268delC | p.Leu757CysfsTer12 | Frameshift | Pathogenic | Premature termination in α-chain; loss of C4a/C4b cleavage site |
| c.1101C>G | p.Asn367Lys | Missense | Likely pathogenic | Disrupts MG domain folding; impaired secretion |
| c.1516G>A | p.Gly506Arg | Missense | Uncertain significance | Alters β-chain structure; potential impact on C4BP binding |

### 4.3 C4B and Systemic Lupus Erythematosus (SLE)

The association between C4B deficiency and SLE is well-established. Homozygous C4B deficiency is present in approximately 3–5% of SLE patients, compared to 1–2% of the general population. The mechanism is multifactorial:

1. **Impaired immune complex clearance**: C4B is essential for the opsonization of immune complexes and their clearance via CR1 on erythrocytes. Deficiency leads to immune complex deposition in tissues, triggering inflammation and tissue damage.
2. **Impaired B-cell tolerance**: C4B (and C4A) are involved in the elimination of autoreactive B cells. Deficiency impairs this process, leading to the survival of autoreactive clones and the production of autoantibodies.
3. **Altered cytokine production**: C4B deficiency may alter the balance of pro-inflammatory and anti-inflammatory cytokines, contributing to the chronic inflammation characteristic of SLE.

### 4.4 C4B and Schizophrenia

GWAS studies have identified the C4A/C4B locus as a major risk factor for schizophrenia. The risk is specifically associated with increased C4A expression, rather than C4B. However, C4B CNV also contributes to the overall complement activity in the brain. The mechanism involves excessive complement-mediated synaptic pruning during adolescence, leading to reduced synaptic density in the prefrontal cortex and other brain regions. This finding has opened new avenues for therapeutic intervention targeting the complement pathway in schizophrenia.

### 4.5 C4B and Age-Related Macular Degeneration (AMD)

Complement dysregulation is a key driver of AMD, and variants in complement genes (CFH, CFI, C3) are well-established risk factors. C4B CNV has also been implicated, with low C4B copy number associated with increased risk of AMD. The mechanism is thought to involve impaired clearance of drusen (extracellular deposits) in the retina, leading to chronic inflammation and retinal pigment epithelial cell death.

### 4.6 C4B in Cancer

C4B expression is frequently dysregulated in cancer. Tumors often upregulate complement inhibitors (e.g., CD46, CD55, CD59) to evade complement-mediated lysis. However, C4B itself can also be dysregulated:

- **Tumor-promoting roles**: C4B deposition on tumor cells can promote chronic inflammation, which may enhance tumor growth and metastasis. C4B can also promote angiogenesis by activating the C3a/C5a signaling pathways.
- **Tumor-suppressive roles**: In some contexts, C4B-mediated opsonization of tumor cells enhances their phagocytosis by macrophages, promoting anti-tumor immunity.
- **Prognostic biomarker**: High C4B expression in tumor tissue has been associated with poor prognosis in several cancers, including lung, breast, and colorectal cancer.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Microbial Evasion of C4B

Pathogens have evolved multiple strategies to evade C4B-mediated complement attack:

#### 5.1.1 Recruitment of Host Complement Regulators

Many pathogens recruit host complement regulators to their surface to inactivate C4B:

- ***Neisseria meningitidis***: Binds C4BP via the porin PorA, recruiting this soluble regulator to the bacterial surface. C4BP then acts as a cofactor for factor I-mediated cleavage of C4b, preventing C3 convertase formation.
- ***Streptococcus pyogenes***: The M protein binds C4BP, and the SIC (streptococcal inhibitor of complement) protein directly binds C4b, preventing its interaction with C2.
- ***Staphylococcus aureus***: The extracellular fibrinogen-binding protein (Efb) and the complement inhibitor SCIN (staphylococcal complement inhibitor) bind C4b and C3b, blocking convertase assembly.
- ***Candida albicans***: Binds C4BP and factor H, inactivating C4b on the fungal surface.

#### 5.1.2 Proteolytic Inactivation of C4B

Some pathogens secrete proteases that cleave C4B:

- ***Pseudomonas aeruginosa***: Elastase cleaves C4B, inactivating it.
- ***Serratia marcescens***: Serratia protease cleaves C4B.
- ***HIV-1***: The HIV-1 protease can cleave C4B, contributing to complement evasion.

#### 5.1.3 Molecular Mimicry

Some pathogens express proteins that mimic C4B or its regulators:

- ***Herpes simplex virus type 1 (HSV-1)***: The glycoprotein gC binds C3b and C4b, acting as a decay-accelerating factor.
- ***Vaccinia virus***: The complement control protein (VCP) binds C4b and C3b, inactivating them.

### 5.2 C4B and Viral Entry

C4B has been implicated in viral entry for some viruses. For example, the Epstein-Barr virus (EBV) uses C3d (a fragment of C3) bound to CR2 (CD21) for B-cell entry. While C4B is not directly involved in EBV entry, C4B-opsonized immune complexes can enhance viral uptake by cells expressing CR1 or CR3, potentially facilitating viral dissemination.

### 5.3 C4B and Bacterial Pathogenesis

The interaction of C4B with bacterial pathogens is a double-edged sword. On one hand, C4B-mediated opsonization promotes bacterial clearance. On the other hand, some bacteria exploit C4B to enhance their survival:

- ***Salmonella enterica***: The O-antigen of lipopolysaccharide (LPS) can bind C4b, but this interaction is not bactericidal and may actually protect the bacteria from MAC-mediated lysis by sterically hindering C5b-9 insertion.
- ***Borrelia burgdorferi***: The outer surface protein OspE binds C4BP, inactivating C4b and promoting bacterial survival.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 C4B as a Therapeutic Target

The complement system is an attractive target for therapeutic intervention in a wide range of diseases, including autoimmune diseases, inflammatory disorders, and neurodegenerative diseases. C4B, as a central component of the classical and lectin pathways, is a potential target for inhibition.

### 6.2 FDA-Approved Drugs Targeting the Complement Pathway

While no drugs directly target C4B, several FDA-approved drugs target upstream or downstream components of the complement pathway:

| **Drug** | **Target** | **Mechanism** | **Indication** |
|---|---|---|---|
| Eculizumab (Soliris) | C5 | Monoclonal antibody; blocks C5 cleavage | Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) |
| Ravulizumab (Ultomiris) | C5 | Monoclonal antibody; long-acting C5 inhibitor | PNH, aHUS |
| Pegcetacoplan (Empaveli) | C3 | Pegylated peptide; inhibits C3 cleavage | PNH |
| Iptacopan (Fabhalta) | Factor B | Small molecule; inhibits factor B, blocking alternative pathway | PNH |
| Sutimlimab (Enjaymo) | C1s | Monoclonal antibody; inhibits C1s, blocking classical pathway | Cold agglutinin disease (CAD) |

Sutimlimab is of particular relevance to C4B, as it inhibits C1s, the protease that cleaves C4B to C4b. By blocking C1s, sutimlimab prevents C4B activation and downstream complement-mediated hemolysis in CAD.

### 6.3 Investigational Drugs Targeting C4B or Its Regulators

Several investigational drugs are being developed to target C4B or its regulatory proteins:

- **C1s inhibitors**: Small-molecule inhibitors of C1s (e.g., C1s-INH-1) are in preclinical development for the treatment of autoimmune diseases.
- **MASP-2 inhibitors**: Narsoplimab (OMS721) is a monoclonal antibody targeting MASP-2, which is being investigated for the treatment of IgA nephropathy and thrombotic microangiopathy.
- **C4BP-based therapeutics**: Recombinant C4BP or C4BP-derived peptides are being explored as anti-inflammatory agents, as they can accelerate the decay of the C3 convertase.
- **C4B-enhancing agents**: In the context of C4B deficiency, gene therapy approaches are being explored to restore C4B expression. Adeno-associated virus (AAV) vectors carrying the C4B gene have shown promise in preclinical models.

### 6.4 Pharmacogenomic Considerations

The CNV of C4B has significant pharmacogenomic implications:

- **Complement inhibitor dosing**: Patients with high C4B copy number may have higher baseline complement activity, potentially requiring higher doses of complement inhibitors.
- **Drug metabolism**: C4B CNV is in linkage disequilibrium with CYP21A2 variants, which can affect drug metabolism. However, this is primarily relevant for drugs metabolized by CYP21A2.
- **Biomarker potential**: Serum C4B levels can serve as a biomarker for disease activity in SLE and other complement-mediated diseases, guiding treatment decisions.

### 6.5 Gene Therapy and CRISPR-Based Approaches

The C4B gene is an attractive target for gene therapy in patients with C4B deficiency. Approaches being explored include:

- **AAV-mediated gene delivery**: AAV vectors carrying the C4B cDNA under the control of a liver-specific promoter could restore C4B expression in the liver.
- **CRISPR/Cas9-mediated gene correction**: For patients with point mutations in C4B, CRISPR/Cas9 could be used to correct the mutation in patient-derived hematopoietic stem cells or hepatocytes.
- **Antisense oligonucleotides (ASOs)**: ASOs could be used to modulate C4B splicing or expression in specific tissues, such as the brain, for the treatment of schizophrenia.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the C4B gene and protein:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 721 | https://www.ncbi.nlm.nih.gov/gene/721 |
| Ensembl | ENSG00000224389 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000224389 |
| UniProt | P0C0L5 | https://www.uniprot.org/uniprotkb/P0C0L5/entry |
| RCSB PDB | 4FXK (C4B-MG2 complex) | https://www.rcsb.org/structure/4FXK |
| HGNC | 1324 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1324 |
| OMIM | 120820 | https://www.omim.org/entry/120820 |
| ClinVar | C4B | https://www.ncbi.nlm.nih.gov/clinvar/?term=C4B%5Bgene%5D |
| dbSNP | C4B | https://www.ncbi.nlm.nih.gov/snp/?term=C4B%5Bgene%5D |
| STRING | P0C0L

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)